
Rox Medical
Stage
Series E | DeadTotal Raised
$97.7MLast Raised
$40MAbout Rox Medical
ROX Medical is an early phase medical device company that is developing a treatment for Chronic Obstructive Pulmonary Disease (COPD). The company's therapy is intended to improve the delivery of oxygen to tissue to treat hypoxemia in COPD patients via the creation of a therapeutic fistula. The company\'s device creates a passage between an artery and a vein in the pelvic region which redirects oxygen rich blood back to the lungs of severe COPD patients.
Loading...
Loading...
Rox Medical Patents
Rox Medical has filed 41 patents.
The 3 most popular patent topics include:
- muscarinic antagonists
- respiratory therapy
- lung disorders

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
1/8/2019 | 12/28/2021 | Vascular diseases, Lung disorders, Respiratory therapy, Rare diseases, Muscarinic antagonists | Grant |
Application Date | 1/8/2019 |
---|---|
Grant Date | 12/28/2021 |
Title | |
Related Topics | Vascular diseases, Lung disorders, Respiratory therapy, Rare diseases, Muscarinic antagonists |
Status | Grant |
Latest Rox Medical News
Dec 18, 2018
News provided by Share this article SAN CLEMENTE, Calif., Dec. 18, 2018 /PRNewswire/ -- ROX Medical, Inc. (ROX), a privately held medical device company pioneering a minimally-invasive therapy for hypertension, today announced the appointment of Jonathan Sackner-Bernstein, MD as its Chief Medical Officer and Executive Vice President of Clinical and Regulatory Affairs. Dr. Sackner-Bernstein brings experiences as engineer, cardiologist, clinical investigator, regulator and innovator to the ROX team. Following his academic career (primarily at Columbia University), Sackner-Bernstein shifted to developing his product development skills. He built and ran a Phase 1 clinical research unit, served in a senior role at the FDA, ran clinical/regulatory for a stem cell therapeutic and consulted for DARPA. Prior to joining ROX, Sackner-Bernstein served as consultant to a wide range of device, drug and biologic companies. Dr. Sackner-Bernstein was recruited to the FDA's Center for Devices as the number 2 in scientific/clinical matters. He led teams across a diverse portfolio – spanning from innovation programs to the post-market safety transformation. Sackner-Bernstein led several Center and Agency level interactions with other Federal Agencies and international regulatory authorities. Following separation from Federal service, Sackner-Bernstein was recruited by DARPA to support the launch of their new Biological Technologies Office. "Dr. Sackner-Bernstein is a broadly experienced physician and seasoned medical device executive with clinical, FDA and medical device company background," commented CEO Michael MacKinnon. "We are thrilled to have Dr. Sackner-Bernstein join the executive team at ROX Medical to progress this exciting technology to the market and potentially become the standard of care in hypertension." "The ROX Coupler represents a transformative opportunity in the treatment of hypertension," explained Sackner-Bernstein. "As angioplasty forever altered the management of coronary disease, so I believe ROX has the opportunity to do for hypertension. Who wouldn't want to join the team in such a pursuit?" About ROX Medical, Inc. ROX® Medical has developed an implantable device and therapy intended to treat uncontrolled high blood pressure. Blood pressure reduction is achieved by diverting a small amount of blood flow from the arterial system into the venous system. The ROX Coupler is a small stent-like device that is placed between the artery and vein located in the upper thigh. The Coupler is about the size of a dime and is easily placed using standard catheter techniques. ROX Medical is conducting the CONTROL HTN-2 clinical trial in the United States for hypertension (visit www.controlhtn2.com for more information). The ROX Medical Coupler is commercially available in Europe under CE mark. SOURCE ROX Medical, Inc
Rox Medical Frequently Asked Questions (FAQ)
Where is Rox Medical's headquarters?
Rox Medical's headquarters is located at 150 Calle Iglesia, San Clemente.
What is Rox Medical's latest funding round?
Rox Medical's latest funding round is Series E.
How much did Rox Medical raise?
Rox Medical raised a total of $97.7M.
Who are the investors of Rox Medical?
Investors of Rox Medical include Versant Ventures, Domain Associates, Apple Tree Partners, Novartis Venture Funds, Prism VentureWorks and 3 more.
Who are Rox Medical's competitors?
Competitors of Rox Medical include Cardiovascular Systems, HistoSonics, Aethlon Medical, Celonova Biosciences, Uptake Medical and 7 more.
Loading...
Compare Rox Medical to Competitors
Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.

ImpediMed is a company that focuses on the development and distribution of medical devices, specifically in the healthcare sector. The company's main products are devices that utilize bioimpedance spectroscopy (BIS) technologies to noninvasively assess and monitor fluid status in patients, aiding in the clinical assessment of potential onset of secondary lymphoedema, particularly in cancer survivors. These devices are primarily used in the healthcare industry, particularly by surgeons, oncologists, therapists, and radiation oncologists. It is based in San Diego, California.

Cerapedics is a privately held medical device company focused on developing and commercializing osteobiologic products based on its anorganic bone mineral (ABM) and synthetic small peptide (P-15) technology platform for use in a wide variety of spine, trauma and orthopedic surgical procedures. i-FACTOR bone graft is a biologic bone graft that utilizes a synthetic small peptide as an attachment factor intended to stimulate the natural bone healing process resulting in safe, predictable bone formation at a fraction of the cost of growth factors. It was founded in 2000 and is based in Westminster, Colorado.
synecor is a medical device developer
Leptos Biomedical is developing an impressive new electrical stimulation device treating obesity.

Moximed develops unicompartmental load absorber implants for active patients with painful knee osteoarthritis (OA). The company offers an implant procedure that do not require bone cutting or bone removal, and, importantly, they absorb excess joint load rather than shift load to other areas of the joint. The company was founded in 2006 and is based in Fremont, California.
Loading...